The abstract is read at the publisher; the summary is JClub's.
Ketoacidosis occurred at an incidence of 2·43 per 1000 person-years during SGLT2 inhibitor treatment episodes in adults with type 2 diabetes across three Scandinavian countries.
- Why it matters: Routine-practice evidence on how often ketoacidosis occurs with SGLT2 inhibitors, which patient factors raise risk, and what happens afterward has been limited.
- What they did: Nationwide registers were used for 322 597 SGLT2 inhibitor-treatment episodes (282 282 patients) with nested case-control analyses matched on age, sex, region of birth, calendar time, and time since initiation.
- The result: Risk was highest shortly after initiation but persisted through follow-up; strong risk factors included HbA1c ≥83 mmol/mol (OR 15·37) and malnutrition (OR 10·54), with infection most common (OR 7·60), and after 1 year insulin use rose to 73·0% among 842 survivors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.